MLV & Co. Initiates Acorda Therapeutics With Buy
MLV & Co. initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Buy rating.
The target price for Acorda Therapeutics is set to $58.
Acorda Therapeutics shares have gained 8.31% over the past 52 weeks, while the S&P 500 index has surged 13.04% in the same period.
Acorda Therapeutics shares rose 4.04% to $38.38 in pre-market trading.
Latest Ratings for ACOR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 2021 | HC Wainwright & Co. | Upgrades | Neutral | Buy |
| May 2020 | HC Wainwright & Co. | Reiterates | Neutral | |
| Oct 2019 | JP Morgan | Downgrades | Neutral | Underweight |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: MLV & Co.Initiation Analyst Ratings
